Most of the in vitro diagnostics (IVD) manufacturers that serve clinical laboratories worldwide reported facing financial “headwinds” in the China IVD market that affected their third-quarter performance. This was due to policy changes in the country that include: • Volume-based procurement (VBP): China’s VBP program purchases medical supplies in bulk to decrease costs. This is […]
Reforms in China Affect IVD Companies’ Q3 2025 Earnings
Most diagnostics companies report growth but face struggles in China’s IVD market
- By Mark Terry
- > From the Volume XXXII, No. 16 - November 17, 2025 Issue
- Tags: Abbott Laboratories, AI, artificial intelligence, BACTEC, BD, Beckman Coulter, Becton Dickinson and Company, Bio-Rad Laboratories, BioFire, bioMerieux, Blackstone, Brian J. Blaser, Cepheid, China IVD market, Danaher Corporation, diagnosis-intervention packet, diagnosis-related group, DIP, DRG, FACSDiscover platform, genomics, Hologic, hs-TnI) Roche Diagnostics, i-STAT High Sensitivity Troponin-I cartridge, i-STAT TBI, immunodiagnostics, immunohematology, in vitro diagnostics, IVD, IVD vendors, ivd/lab informatics, Jochen Schmitz PhD, leica biosystems, Marc Casper, Matt Sause, microbiology, molecular diagnostics, multiplex diagnostic test, next generation sequencing, NGS, Norman Schwartz, Parse Biosciences, pcr, Qiagen, QuidelOrtho, Rainer Blair, Robert Ford, Roche Group, Roop Lakkaraju, Seeking Alpha, Siemens Healthineers, single-cell sequencing, single-plex test, SPOTFIRE, Stephen MacMillan, sysmex, Thermo Fisher Scientific, Thierry Bernard, Thomas Schiniecker PhD, Tom Polen, TPG, transplant diagnostics, VBP, VIDAS PCT, volume-based procurement, Waters Corporation
